Philadelphia biopharm firm Context Therapeutics files plans for IPO

Another local life sciences company is looking to go public.

Context Therapeutics, a Philadelphia biopharmaceutical company focused on women’s cancers, is seeking to raise about $20 million through its IPO.

In documents filed Monday with the Securities and Exchange Commission, Context states it intends to sell 1.5 shares million of its common stock to the public at $12 to $14 per share.

The company is poised to become the fifth Philadelphia-area life sciences to complete an IPO this year. That distinction, however, could go to Castle Creek Biosciences, a cell and gene therapy company based in Exton that filed plans to go public through a $100 million IPO in July. Neither company has set a specific date for their public offering.

Context plans to list its stock on Nasdaq under the symbol “CNTX.”

Read the full article at:

The following two tabs change content below.
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.